A mbulatory electrocardiographic monitoring has been widely used to identify and quantify complex ventricular arrhythmias in an effort to explain potentially related symptoms and to identify patients at increased risk of sudden fl-blockers'2-14; for the more commonly used class I drugs, evidence is sparse and controversial. [15] [16] [17] [18] [19] [20] The hypothesis that antiarrhythmic therapy may reduce arrhythmic death is currently being tested in a large mortality trial, the Cardiac Arrhythmia Suppression Trial (CAST).21 (Preliminary results of CAST suggest that some agents that reduce PVCs may increase risk. 22) The determination of the effects of pharmacological interventions on PVCs for both symptom relief and potential risk reduction is complicated by spontaneous variations in their frequency, which can mimic drug effect.23-32 Several guidelines for distinguishing therapeutic antiarrhythmic drug effects from spontaneous variability have been proposed as a result of these and other observations.25-32 These guidelines are based on variability data derived from recordings obtained while off antiarrhythmic therapy, both at baseline (often including consecutive recordings) and at follow-up, separated by varying time intervals.
However, little data are available on the variability of PVCs during continuous treatment with a constant regimen of antiarrhythmic drug. Because suppression of ventricular arrhythmias is used as an end point for drug efficacy, in both clinical trials and practice, spontaneous variability during treatment may be a source of confusion and, as such, important to recognize. Substantial increases in arrhythmia rates during treatment might be alarming to the clinician and lead to a change in drug dosage or to drug withdrawal. However, if an observed increase in ventricular arrhythmia is the result of transient, spontaneous variability, a more conservative approach to changes in treatment may be warranted for nonlife-threatening arrhythmias. If due to spontaneous variability, the increased rate of arrhythmia would, by definition, subside spontaneously with time.
The purpose of the present study was to assess arrhythmia variability during chronic therapy for ventricular arrhythmias, to describe how often and in what type of patients clinically noteworthy variability and loss in suppression occur, and to provide guidelines to discriminate true loss of drug efficacy from spontaneous arrhythmia variability.
Methods

Patient Selection Criteria
Consecutive patients enrolled in PVC therapy studies20,33-37 in our clinic were included in the analysis if they had shown arrhythmia suppression on initial drug titration, had undergone serial ambulatory electrocardiographic monitor evaluations over time during chronic therapy, had been constantly maintained on the initially effective drug and drug dose, and had been clinically stable [e.g., no intercurrent myocardial infarction (MI) 
StatisticalAnalysis and Classification of Response
The primary data used in the analysis were the hourly rates of total PVCs and (when present) repetitive PVCs on 24-hour Holter recordings during a 1-day baseline (off drug) and subsequent intermittent days of monitoring during drug therapy. Notice that on-drug recordings are referenced to the one or two consecutive off-drug baseline recordings in all analyses and that off-drug recordings have been shown to show substantial variability over time. 32 The pattern of variability during follow-up was used to classify long-term response of individual patients into six mutually exclusive categories, as defined in the legend to Figure 2 . Both total and repetitive PVCs were used in this classification, and the K statistic was used to test the association between the classes for total and repetitive PVCs. (Tables 2 and 3 ).
The logarithm of the ratio of treatment to baseline PVC rates (log ratio) was computed as follows: log{[PVCs/hr(on drug) +c]/[PVCs/hr(baseline) +c]} The constant, c= 1, needs to be added to the PVC rates to allow for computation even when there are no PVCs (complete suppression). The distribution of the log ratio was normal ( Figure 1A ), especially at the upper end of the distribution, which makes computation of upper confidence limits appropriate. The same procedure was followed for repetitive beats in patients with more than one repetitive beat per hour at baseline (24 patients), although the resulting distribution was not normalized as well ( Figure 1B) . Thus, conclusions regarding repetitive beats should be qualified by the reduced number of patients observed and by nonnormality in the log ratio of repetitive PVCs per hour.
The analysis of variance procedures of Pratt et a128 were applied to the log ratios. These procedures provide estimates of central tendency and variability within individual patients that can be pooled over a group of patients. The pooled mean of the individual log ratios (m) is converted to percent change (m%) by m% = 1O0(1lO-1) and m and the SDs (s) based on the pooled variance of the individual log ratios were used to define the upper bound (ub) of the one-tailed 95% confidence interval of the log ratio according to ub=m+ 1.65s The upper bound of the log ratio is converted to the upper bound of percent change (ub%) by ub%= 100 (10ub-1) The m% and ub% were used descriptively, whereas m and S2 were used to identify differences among subgroups of patients. Specifically, the analysis of variance was used to test for differences in the (Figure 2 and Tables 2 and 3 ) and by quantitative analyses of levels of and variability in suppression (Tables 2 and 3 ). In this study of treated arrhythmias, a statistically important relation was not found between time from baseline to chronic testing and variability in arrhythmia suppression (Figure 3) .
Averaged over all patients, the log ratio during therapy was -1.097, with variance of 0.285 for total Analysis of overall response was also performed for patients (n =48) meeting the more stringent entry criterion of 80% or more suppression of total PVCs, with similar results: average suppression was 93%, variance in the log ratio was 0.308, and 95% confidence bound was 44%.
As defined by changes in categories of PVC suppression ( Figure 2 and Table 2 ), 29 Response was determined for several patient subgroups based on specific baseline characteristics (Tables 2 and 3) .
Age. Variability (variance) in suppression did not differ between younger (<64 years) and older (>64 years) patients for total or repetitive PVCs. However, older patients tended to show lower average total PVC suppression. The 95% confidence limits, which are strongly influenced by differences in average suppression, also differed significantly, with older patients requiring a greater fall in suppression to exceed the one-sided bound of spontaneous variability. In parallel with this, a larger percentage of older patients showed loss of suppression during follow-up (p=0.03). However, differences for repetitive beats did not approach significance.
Sex. Men tended to show greater variability in suppression of total PVCs than women (p<0.06). Men had similar (to slightly lower) average suppression, but a greater fall in suppression was required for men to exceed the 95% confidence bound. In parallel with this greater variability, men tended to more frequently show a pattern of intermittent loss of suppression during follow-up (p =0.11). Gender differences for repetitive beats were not significant.
Disease etiology. Variance in suppression of total PVCs was significantly less for groups both with coronary artery disease (p<O0.03) and with recent MI .w (p=0.05). However, patients with coronary artery disease also tended to show slightly lower average suppression. The net result was that the 95% confidence limits were similar for groups with and without coronary artery disease, and a similar proportion in each group lost suppression during serial observations. For repetitive beats, less variance was noted for recent MI (but not for coronary artery disease in general), but average suppression of repetitive beats was also less. The net result was that the confidence limits and percent of patients losing suppression were similar in the groups with and without recent MI.
Left ventricular function. Poor left ventricular function (ejection fraction, <0.5) was associated with a trend toward greater variability in suppression that was nonsignificant for total PVCs (p<0.34) but significant for repetitive PVCs (p=0.012). Lower ejection fraction was also associated with a trend toward lower average percent suppression for total (but not repetitive) PVCs (p=0.10). The net result for total PVCs was that in patients with poor left ventricular function, substantially greater falls in suppression were required to exceed the 95% one-sided confidence bound for spontaneous variability of suppression. In parallel with this, almost twice as many patients with low ejection fraction showed "loss of suppression" sometime during follow-up (p.0.03). In the smaller group of patients with repetitive PVCs, differences in confidence bounds and frequency of losing suppression did not emerge.
Baseline arrhythmia frequency. Variability in percent suppression was significantly greater in patients with more than the median arrhythmia frequency, for both total PVCs (p<O0.003) and repetitive beats (p<0.04). However, average suppression was also significantly greater in the higher frequency subgroup for both total (p<0.002) and repetitive beats (p<0.02). The 95% confidence bounds, which are more strongly influenced by differences in suppression, were more removed (lower) from the target suppression of total and repetitive PVCs for those with lower frequency (less than the median) PVCs. (The chance of losing suppression was also slightly but not significantly greater in those with lower frequency PVCs at baseline.)
13-Blocker therapy. Variability in suppression was significantly greater for total (p=0.007) as well as repetitive PVCs (p<0.02) in patients given 13-blocker therapy. However, mean suppression of both total and repetitive PVCs also tended to be greater in 13-blocked patients. The net result was similar 95% confidence limits for spontaneous variability in each group and similar frequencies of patients losing suppression.
Antiarrhythmic drug class. Drugs were subgrouped into class IC (encainide and flecainide), other class I drugs (imipramine, moricizine, and recainam), and class II/III (sotalol) and compared (Tables 2 and 3 ). Significant differences in variance were observed among these drug groups (p<0.05). In this comparison, variances in PVC suppression were least during encainide/flecainide therapy. Encainide/flecainide also tended to be associated with less individual loss of suppression, but differences were not significant.
Bivanate Relations Among Baseline Factors Associated With Vaniability
The interrelatedness of several of the factors individually associated with PVC variance was explored by a step-down log linear analysis. Significant (p<0.05) two-way interactions included A) a diagnosis of recent MI with 1) a diagnosis of coronary artery disease, 2) a lower baseline frequency of PVCs, 3) use of class IC agents, and 4) use of 13-blockers and B) gender with 1) a diagnosis of coronary artery disease and 2) frequency of PVCs at baseline.
Discussion
Our study evaluated variability in suppression of chronic ventricular arrhythmias both quantitatively and qualitatively during constant, initially "effective" antiarrhythmic drug therapy and found this variability to be complex and substantial. Variability was defined quantitatively by the variance in suppression, and the ratio of variances was used to test the significance of differences in variability between subgroups. The one-sided 95% confidence bound of suppression for spontaneous variability was also determined for the entire group and for subgroups and was found to be strongly influenced by differences in average levels of arrhythmia suppression as well as by variance. The frequency of loss of suppression during repeated testing, defined when clinically determined bounds (i.e., 70%, 90% suppression) were exceeded, generally varied in parallel with variations in the 95% confidence bounds.
Variability might also be influenced by changes in substrate (e.g., intervening MI), changes in compliance, or changes in drug metabolism. None of these within-patient independent variables was evaluated in the present study, except by the inclusion criteria, which specified that patients be clinically stable on entry. Differences in numbers of monitored tests and time intervals of observation are other factors that might influence variability results. However, the influence of these factors was minimized in our study by design. Despite this. loss of arrhythmia suppression occurred at least once during the median followup of 11 months in 40-50% of patients.
Greater variability (variance) in suppression was found to be associated with several baseline characteristics, including 1) greater than the median initial PVC frequency, 2) 13-blocker therapy, 3) of patients in our study suggest substantial "primary" arrhythmia variability during treatment. Figure 4 shows a hypothetical rate of PVCs during baseline and a reduced but parallel rate of PVCs during treatment with an "effective" antiarrhythmic agent. Note that cycles of increasing (and decreasing) PVC frequency also occur during treatment, even though antiarrhythmic therapy maintains a constant percentage reduction in PVCs, because the spontaneous rate is changing cyclically over time. Not only does this suggest that chronic efficacy of therapy, based on a percentage arrhythmia reduction, cannot be decided by an absolute criterion, but it also illustrates the problem of using a temporally distant baseline for determining current and ongoing PVC suppression, as suggested by the examples shown in the figure and described in the figure legend.
Study Limitations
The present study shares the limitations of all retrospective studies. The number of monitored tests and time interval over which evaluations were made varied, although about 85% of patients clustered close to the median of five observations during 11 months. Greater weight should be placed on conclusions regarding total instead of repetitive PVCs because of the smaller number of patients with repetitive PVCs at baseline and because of departures from normality in the distribution of the log ratios of repetitive PVCs. Our findings for subgroups should also be tempered by the relatively limited number of patients in many of these groups. Also, subgroup hypotheses were not formulated prospectively, and analyses were derived from groups of variable size. However, several of the factors we found to affect variability during treatment have also been found to be important by others in other groups of untreated (and treated) patients.32,39 Patients with a history of sustained ventricular tachycardia or cardiac arrest were excluded. Treatment variability may possibly differ in these groups with more malignant arrhythmias. (However, electrophysiological testing is increasingly being viewed as a better evaluation method than Holter monitoring in these latter patients.40-42) Drugs and drug subclasses were not all represented or were represented in relatively small numbers. However, our observations suggest that some variability will be seen with all antiarrhythmic therapy, although the degree of variability may be less with some drugs (i.e., class IC agents). Finally, the individual factors associated with greater PVC variability were often interrelated, in some cases by well-known clinical associations and in other cases by study design features. Thus, the independent contributions of these factors could not be definitively determined, although hypotheses may be generated for future studies.
Clinical Implications
What are the clinical implications of variations in arrhythmia rates during treatment? Because present criteria for assessing treatment success are more arbitrary than scientifically based, only tentative answers can be given. Our observations suggest that the clinician should strongly consider intrinsic variation in arrhythmia frequency as well as true loss of pharmacological effect to explain variations in rates of arrhythmia and arrhythmia suppression during therapy. Rather than making a hurried decision to change drug or drug dose based on increased arrhythmia frequency in patients with symptomatic but non-life-threatening arrhythmias in a single recording, a physician may wish to first obtain a second (confirmatory) monitor at an acceptable follow-up interval (e.g., 1 Therapeutic implications of arrhythmia variability during treatment must also be put in perspective with recent findings in CAST,22 in which encainide and flecainide not only failed to reduce the risk of sudden death but also increased mortality. One possible explanation for a lack of efficacy of antiarrhythmic therapy to reduce sudden death may be that transient or periodic apparent loss of efficacy, as evidenced by transient increases in ectopy, might be a mechanism whereby fatal ventricular tachycardia or fibrillation could occur during apparently "effective" therapy with an antiarrhythmic drug. The implication in this case would be a more aggressive approach to monitoring arrhythmia suppression when antiarrhythmic therapy is given for risk reduction. However, suppression associated with encainide and flecainide was greater and variability was less than with the other antiarrhythmic agents; moreover, the problem in CAST was an increase in risk, not simply failure of risk reduction. Thus, other explanations should be considered for the CAST results. Certain antiarrhythmic drugs may possess excessive proarrhythmic potential (i.e., may predispose to sustained ventricular tachycardia or fibrillation, perhaps especially in the setting of ischemic disease), distinct from their antiectopic effects, that unfavorably tips the risk-tobenefit ratio for treatment in some patient groups. Another possibility is that asymptomatic PVCs in postinfarction patients may be "markers" of excessive risk but not causally related to the initiation of fatal ventricular arrhythmias. In this case, antiectopic therapy may be generally ineffective for sudden death reduction. Treatment would then be useful only for symptomatic arrhythmia control and not for prophylactic risk reduction. Findings in the ongoing (moricizine) limb of the CAST study will be instructive in answering some of these questions, as will the results of other ongoing therapeutic trials for risk reduction in patients with prognostically important ventricular arrhythmias.
Conclusion
Our findings suggest that variability in percent suppression of ventricular arrhythmia is often observed in patients undergoing chronic treatment with antiarrhythmic drugs. This variability may be frequently seen as an increase in arrhythmia rates above the level targeted for drug efficacy (and occasionally, even to above baseline rates). However, these variations in rate often later return toward levels considered to be efficacious. Thus, careful consideration should be given before an adjustment in dose or change in antiarrhythmic agent is undertaken, particularly when rates during treatment are compared with a single initial baseline recording distant in time. Consistent trends on multiple recordings may be required to establish a true loss of drug efficacy or a progression of arrhythmic disease mandating a change in treatment approach.
